GeneDx Holdings Corp. (NASDAQ:WGS) Shares Purchased by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board boosted its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 131.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 88,000 shares of the company's stock after purchasing an additional 50,000 shares during the period. Canada Pension Plan Investment Board owned approximately 0.32% of GeneDx worth $6,764,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. State Street Corp increased its holdings in shares of GeneDx by 18.3% in the third quarter. State Street Corp now owns 314,914 shares of the company's stock valued at $13,365,000 after purchasing an additional 48,735 shares during the period. Barclays PLC raised its stake in shares of GeneDx by 346.3% during the 3rd quarter. Barclays PLC now owns 18,921 shares of the company's stock worth $803,000 after buying an additional 14,681 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of GeneDx by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 377,631 shares of the company's stock valued at $16,030,000 after buying an additional 30,379 shares during the period. Tidal Investments LLC purchased a new stake in shares of GeneDx in the third quarter valued at approximately $514,000. Finally, Franklin Resources Inc. acquired a new position in GeneDx during the third quarter worth $301,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Kevin Feeley sold 15,516 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $92.18, for a total value of $1,430,264.88. Following the sale, the chief financial officer now directly owns 1,726 shares of the company's stock, valued at approximately $159,102.68. This trade represents a 89.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Katherine Stueland sold 1,657 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36. Following the transaction, the chief executive officer now directly owns 3,937 shares of the company's stock, valued at $308,975.76. This trade represents a 29.62 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 138,780 shares of company stock worth $12,907,437. 27.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on WGS shares. The Goldman Sachs Group raised their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. TD Cowen lifted their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $72.33.

GeneDx Price Performance

WGS traded up $1.62 during midday trading on Friday, reaching $111.01. 619,079 shares of the company's stock were exchanged, compared to its average volume of 699,336. The business's 50-day moving average price is $95.78 and its 200 day moving average price is $82.00. The stock has a market capitalization of $3.12 billion, a PE ratio of -56.64 and a beta of 1.93. GeneDx Holdings Corp. has a 1-year low of $10.70 and a 1-year high of $115.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. The firm had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. As a group, equities analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.